Healthcare Review: Halozyme Therapeutics, Keryx Biopharmaceuticals, Sunesis Pharmaceuticals & Cytori Therapeutics Are Top Movers Print E-mail
By Staff and Wire Reportds   
Friday, 21 September 2012 13:17
Stocks jumped on Friday as Apple unveiled its latest iPhone worldwide, driving its shares up to a new peak, and Spain appeared to move closer to an anticipated bailout package. In economic news, Spain is considering freezing pensions and speeding up a planned rise in the retirement age as it races to cut spending and meet conditions of an expected international sovereign aid package, sources with knowledge of the matter said.

shares dropped 9.57% to $21.43 after the company expects an opinion recommending against approval of the Marketing Authorization Application or MAA for Qsiva for obesity. The formal decision from the CHMP is anticipated following their October 2012 meeting. If a negative recommendation is issued in October, and depending on the nature of the objections, the company would either resubmit the MAA at a later date or appeal this decision and request a re-examination by the CHMP. Several healthcare stocks are making notable news at mid day on Friday.

Halozyme Therapeutics, Inc.(NASDAQ:HALO)
shares surged 26.83% to $8.13 after ViroPharma and HALO announced the U.S. Food & Drug Administration has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20. The FDA has advised ViroPharma to amend the study protocol, allowing for increased laboratory sampling to monitor rHuPH20 antibody levels, and keep the Agency informed of elevated antibody levels during the treatment phase of the study.  

Keryx Biopharmaceuticals(NASDAQ:KERX)
shares jumped 13.71% to $2.83. Keryx‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a report released on Sept. 5. Additionally, analysts predict that Keryx Biopharmaceuticals will post $-0.30 earnings per share for the current fiscal year. KERX is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.

Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS)
shares climbed 9.31% to $5.52 after Cowen reaffirmed their outperform rating on shares of SNSS in a research note released today.

Additionally, the company announced the closing of two previously disclosed financings. Royalty Pharma has invested $25.0 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of lenders have funded the second tranche of $15.0 million under their $25.0 million loan facility with the company.

Cytori Therapeutics Inc. (USA)(NASDAQ:CYTX)
stock jumped 7.51% to $4.58. The company announced that its Chief Executive Officer, Mr. Christopher Calhoun, will present at Noble Financial Capital Markets' BIOX Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September 24 at 9:30 AM ET.

shares climbed 6.75% to $2.69 in the early hour. Dyax Corp and Kadmon Corporation, LLC (Kadmon) announced that they have entered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective antibody inhibitor of matrix metalloproteinase 14 (MMP-14).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus